医学
心力衰竭
背景(考古学)
再生(生物学)
细胞疗法
疾病
心脏病学
临床试验
立场文件
内科学
心脏病
重症监护医学
离体
生物信息学
干细胞
病理
体内
生物技术
遗传学
细胞生物学
生物
古生物学
作者
Rosalinda Madonna,Linda W. van Laake,Sean M. Davidson,Felix B. Engel,Derek J. Hausenloy,Sandrine Lecour,Jonathan Leor,Cinzia Perrino,Rainer Schulz,Kirsti Ytrehus,Ulf Landmesser,Christine L. Mummery,Stefan Janssens,James T. Willerson,Thomas Eschenhagen,Péter Ferdinandy,Joost P. G. Sluijter
标识
DOI:10.1093/eurheartj/ehw113
摘要
Despite improvements in modern cardiovascular therapy, the morbidity and mortality of ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and worldwide. Patients with IHD may benefit from therapies that would accelerate natural processes of postnatal collateral vessel formation and/or muscle regeneration. Here, we discuss the use of cells in the context of heart repair, and the most relevant results and current limitations from clinical trials using cell-based therapies to treat IHD and HF. We identify and discuss promising potential new therapeutic strategies that include ex vivo cell-mediated gene therapy, the use of biomaterials and cell-free therapies aimed at increasing the success rates of therapy for IHD and HF. The overall aim of this Position Paper of the ESC Working Group Cellular Biology of the Heart is to provide recommendations on how to improve the therapeutic application of cell-based therapies for cardiac regeneration and repair.
科研通智能强力驱动
Strongly Powered by AbleSci AI